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Rhabdomyosarcoma (RMS) is a highly malignant and metastatic pediatric can-
cer that arises from the skeletal muscle. Recent studies have identified an impor-
tant role of AKT signaling in RMS progression. This suggests targeting components 
of the PI3K/Akt pathway may be an effective therapeutic strategy. Here, we inves-
tigated the in vitro activity of the class I PI3K inhibitors [1] in human rhabdomyo-
sarcoma cell lines (embryonal rhabdomyosarcoma RD and A204, alveolar rhabdo-
myosarcoma SJCRH30). We used a panel of four compounds which specifically tar-
get PI3K isoforms including the PI3Kα-selective (p110α ) inhibitor alpelisib BYL719, 
currently in clinical development by Novartis Oncology, the p110β TGX-221 inhibitor, 
the p110γ CZC24832, the p110δ CAL-101inhibitor and the dual p110α/p110δ inhibi-
tor AZD8835. The effects of single drugs and of several drug combinations were 
analyzed to assess cytotoxicity by MTT assays, cell cycle by flow cytometry , apop-
tosis by caspase 3/7 assay and Western blot, as well as the phosphorylation status 
of the pathway. BYL719 treatment resulted in G1 phase cell cycle arrest and apopto-
sis. BYL719 administered in combination with CAL-101, for 48 h and 72h, decreased 
cell viability and induced apoptosis in a marked synergistic manner. Taken together, 
our findings indicate that BYL719, either alone or in combination with p110δ CAL-
101inhibitor, may be an efficient treatment for human rhabdomyosarcoma cells that 
have aberrant upregulation of the PI3K signaling pathway for their proliferation and 
survival.
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